Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  04:03 2022-12-02 pm EST
110.04 USD   +0.22%
12/02Merck Could Retain Keytruda Patent With New Formulation
MT
12/02Compass Therapeutics, Inc. - a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases
AQ
12/01Sector Update: Healthcare Stocks Ending Slightly Higher
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck & Co. Awards Sinopharm Chinese Distribution Rights For COVID-19 Drug

09/29/2022 | 12:33am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
MERCK & CO., INC. 0.22% 110.04 Delayed Quote.43.58%
SAB BIOTHERAPEUTICS, INC. 8.65% 1.13 Delayed Quote.-85.53%
SINOPHARM GROUP CO. LTD. 2.31% 18.62 Delayed Quote.7.31%
All news about MERCK & CO., INC.
12/02Merck Could Retain Keytruda Patent With New Formulation
MT
12/02Compass Therapeutics, Inc. - a clinical-stage, oncology-focused biopharmaceutical compa..
AQ
12/01Sector Update: Healthcare Stocks Ending Slightly Higher
MT
12/01Compass Therapeutics Doses First Patient in Trial of its CTX-471 Immunotherapy Combined..
MT
12/01Transcript : Merck & Co., Inc. Presents at 5th Annual Evercore ISI HealthCONx..
CI
12/01First Wave BioPharma Files IND For Enhanced Formulation Of Adrulipase; Topline Results ..
AQ
12/01Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th ..
BU
11/29Merck Declares Quarterly Dividend of $0.73 Per Share; Payable Jan. 9 to Shareholders of..
MT
11/29Merck Announces First-Quarter 2023 Dividend
BU
11/29Merck & Co., Inc. Announces Dividend for the First Quarter of 2023, Payable on January ..
CI
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 59 072 M - -
Net income 2022 14 812 M - -
Net Debt 2022 18 689 M - -
P/E ratio 2022 18,9x
Yield 2022 2,54%
Capitalization 279 B 279 B -
EV / Sales 2022 5,04x
EV / Sales 2023 4,97x
Nbr of Employees 67 500
Free-Float 70,8%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 110,04 $
Average target price 109,61 $
Spread / Average Target -0,39%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.43.58%278 995
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.78%285 774